This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
SYK Stock Rises Following the Launch of Next Generation SurgiCount+
by Zacks Equity Research
Stryker launches the next generation of SurgiCount+ to boost sponge management and blood loss assessment in hospitals.
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Boston Scientific Stock Gains From Market Expansion, Innovation
by Zacks Equity Research
BSX's Endoscopy business within MedSurg is gaining from strong worldwide demand for its broad range of gastrointestinal and pulmonary treatment options.
Stryker Stock Gains on Q3 Earnings Beat & Raised Guidance
by Zacks Equity Research
SYK's third-quarter results reflect strong segmental performance, along with a rise in operating margin.
Here's What Key Metrics Tell Us About Stryker (SYK) Q3 Earnings
by Zacks Equity Research
Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Stryker (SYK) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Stryker (SYK) delivered earnings and revenue surprises of 3.24% and 2.31%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Strong Segmental Performance to Drive Stryker's Q3 Earnings
by Zacks Equity Research
SYK's third-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.
Insights Into Stryker (SYK) Q3: Wall Street Projections for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Stryker (SYK) for the quarter ended September 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
GE HealthCare Acquires Intelligent Ultrasound's Clinical AI Business
by Zacks Equity Research
GEHC acquires clinical AI business to aid its ultrasound portfolio with AI-driven image analysis tools.
SNN Boosts Knee Revision Surgery With Its LEGION Hinged Knee System
by Zacks Equity Research
Smith & Nephew introduces the LEGION Hinged Knee System with OXINIUM Technology, elevating knee revision surgery through innovation.
Globus Medical Expands Orthopedic Trauma Portfolio With New Launches
by Zacks Equity Research
GMED launches ANTHEM II Distal Radius Volar Plates, AUTOBAHN Trochanteric Nail PRO Instruments and CAPTIVATE SOLA Headless Screws.
Should You Invest in the iShares U.S. Medical Devices ETF (IHI)?
by Zacks Equity Research
Sector ETF report for IHI
PBH vs. SYK: Which Stock Is the Better Value Option?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Stryker Stock Gains 18.6% YTD: What's Driving its Share Price?
by Zacks Equity Research
Styker's flagship, Mako Total Knee Platform, its strategic acquisitions and a diversified product portfolio raise optimism about the stock.
SYK Stock May Gain From Completion of Vertos Medical Acquisition
by Zacks Equity Research
Stryker completes the acquisition of Vertos Medical to expand its interventional pain management solutions.
Reasons to Retain Stryker Stock in Your Portfolio for Now
by Zacks Equity Research
SYK continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio.
Stryker Shares May Gain on the Completion of the Acquisition of NICO
by Zacks Equity Research
SYK completes the acquisition of NICO to strengthen its portfolio of solutions for tumor resection and the treatment of ICH.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Stryker Stock Declines Despite Completion of care.ai Acquisition
by Zacks Equity Research
SYK completes the acquisition of care.ai, adding AI-based workflows and smart room technology to its portfolio to overcome nursing shortages, and improve staff retention and workplace safety.
Here's How Much a $1000 Investment in Stryker Made 10 Years Ago Would Be Worth Today
by Zacks Equity Research
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
SYK Stocks Gains Following Expansion of Foot & Ankle Portfolio
by Zacks Equity Research
Stryker unveils two new products, enhancing precision and outcomes in foot and ankle surgeries.
PBH or SYK: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
PBH vs. SYK: Which Stock Is the Better Value Option?
Why Is Stryker (SYK) Up 8.8% Since Last Earnings Report?
by Zacks Equity Research
Stryker (SYK) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.